Rizatriptan oral film - IntelGenx

Drug Profile

Rizatriptan oral film - IntelGenx

Alternative Names: INT 0008/2007; INT0008; RHB-103; Rizaport; Rizatriptan benzoate oral thin film - IntelGenx/RedHill Biopharma

Latest Information Update: 17 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IntelGenx Corp.
  • Developer Grupo Juste; IntelGenx Corp.; RedHill Biopharma
  • Class Antimigraines; Small molecules; Triazoles; Tryptamines
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Migraine

Highest Development Phases

  • Registered Migraine

Most Recent Events

  • 09 Aug 2018 Committee for Medicinal Products for Human Use includes rizatriptan oral film in the list of medicines within the informative note
  • 19 Jun 2018 IntelGenx receives patent allowance for VersaFilm™ technology in European Union
  • 29 Mar 2018 RedHill Biopharma terminates its worldwide licence for rizatriptan oral film
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top